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A dynamic compartmental model was instantiated with recent epidemiological data from 
South Africa to compare the effectiveness and cost-effectiveness of different portfolios of 
interventions to prevent HIV infection over a twenty year time horizon. We hypothesized 
that portfolios which combined scaling up the delivery of highly active antiretroviral 
therapies (HAART), increasing availability of HIV screening and counseling, and 
establishing widespread circumcision campaigns would be the most effective and most 
cost-effective strategies. Portfolios which utilized widespread circumcision for adult men 
were found to be the most cost-effective, while portfolios which utilized a combination of 
interventions were found to be the most effective, in terms of quality adjusted life years 
(QALYs) gained.  These findings highlight the urgency of scaling up access to life-saving 
antiretroviral treatments, and providing concomitant investments in HIV prevention and 
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1.1 HIV in South Africa 
 South Africa remains one of the countries most severely devastated by the HIV 
epidemic.  It is estimated that at  the end of 2007 there were approximately 5.7 million 
people living with HIV in the country, and this number grows daily [1].  The prevalence 
among individuals aged 15-49 approaches 20%, demonstrating the impact of the virus on 
the most productive members of society.  An estimated 1,000 people die from AIDS in 
South Africa each day, accounting for nearly half of all deaths in South Africa and 71% 
of deaths among individuals aged 15-49 [2].   
 In addition to the enormous social burden of the disease, the HIV/AIDS epidemic 
has had major economic consequences for South Africa.  Disease-related morbidity and 
mortality have led to losses in the labor market, reduced labor productivity, and reduced 
exports [3].  Various indicators of human development have fallen sharply, as the country 
struggles to mount a sufficient response against the epidemic.  HIV consumes a 
significant amount of national resources and health resources, hindering the ability of the 
government to address other national needs.  
 
1.2   Current interventions for HIV 
 Although the situation remains urgent, progress has been made in recent years by 
a large coalition of non-governmental organizations, universities, international donors, 
governments, and more.  These agencies include the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria, the United States’ Emergency Plan for AIDS Relief, and the 
World Bank’s Multi Country AIDS Projects. Changes in South African government 
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policy have increased funding for provision of HIV treatment services, while also scaling 
up other interventions including screening and health education. The Joint United Nations 
Program on HIV/AIDS (UNAIDS) reports that  in low- and middle-income countries, 
28% of adults with advanced HIV infection were receiving antiretroviral therapy in 2007 
[1].  The number of HIV positive pregnant women receiving antiretroviral therapy for 
reduction of mother to child transmission increased to 66%. [4]   Additionally, a survey 
estimated that 100% of schools in South Africa included HIV/AIDS education in the past 
year [4]. 
 Although these statistics demonstrate improvement, substantial work remains. A 
UNAIDS report estimated that $27 billion was needed for global HIV/AIDS prevention 
between 2005 and 2007 but that only about $18 billion would be available [5]. Recent 
trials for HIV vaccines and microbicidal gels have been very disappointing. With new 
infections occurring every day, the need for HIV services is likely to continue to grow in 
the most severely affected countries utilizing current strategies for treatment and 
prevention. 
  While resources available to combat the epidemic in South Africa have 
increased, policy makers must make difficult decisions about how to optimally distribute 
a finite amount of resources among a number of potentially beneficial strategies.  
Examples of treatment interventions include provision of antiretroviral medications for 
infected patients and provision of prophylaxis against opportunistic infections. Preventive 
interventions include HIV/AIDS education, distribution of condoms, prevention of 
mother to child transmission, voluntary counseling and testing services (VCT), and 
behavioral interventions for injection drug users such as needle-exchange and methadone 
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maintenance programs.  More recently, male circumcision has also been demonstrated to 
be an effective tool for reducing heterosexual transmission of HIV among men in 
Africa.[6-8]    
Each of these interventions has direct and indirect costs and benefits that warrant 
careful evaluation prior to implementation. Each intervention has the potential to improve 
population health by preventing new HIV infections among uninfected individuals, 
diagnosing infected individuals and providing a critical link to care, reducing disease-
related morbidity and mortality, or some combination of the above.  Whether the 
potential benefits of each intervention warrant their expense is an important consideration 
that should be evaluated prior to implementation.  Moreover, by assessing the costs and 
benefits of implementing multiple HIV interventions simultaneously, policymakers can 
compare the relative trade-offs of each intervention and allocate limited resources for 
HIV prevention and treatment more effectively. 
 
1.3 Mathematical models of the HIV epidemic 
 Policy decisions about resource allocation have significant implications for 
individuals infected with HIV, as well as those at risk for infection.  In this setting, 
mathematical models of HIV epidemics have become increasingly popular tools for 
informing decisions about how to optimize limited resources to achieve certain goals.  
Epidemic models can be used to estimate factors including HIV incidence, prevalence, 
and mortality, in specified populations with varying degrees of granularity.  Because of 
the vast biological, social, and political complexities of HIV epidemics these models are 
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intended to compare the potential gains from implementing particular interventions, 
rather than predict the future course of the epidemic with certainty.   
 Multiple papers have been published recently that aim to use HIV epidemic 
models to inform decisions about health policy and resource allocation in South Africa. 
Granich et al used a novel epidemic model of HIV to analyze  a strategy of widespread 
screening for HIV with immediate initiation of antiretrovirals [9]. Their paper found that 
their proposed strategy would accelerate the transition of the epidemic from an endemic 
phase to an elimination phase, and that it could reduce HIV incidence and mortality to 
less than one case per 1000 people by the year 2016 [9].   Andersson et al used a model to 
examine the possible impact of a partially effective HIV vaccine on the heterosexual HIV 
epidemic in South Africa [10]. Their paper found that even a modestly effective vaccine 
could provide enormous benefits in preventing HIV infections, but also emphasized the 
importance of concurrent educational programs to reduce risk behaviors.  Another paper 
found that migration patterns likely increased high-risk sexual behavior, facilitating HIV 
transmission in South Africa [11]. Models have also been used to analyze how different 
interventions might simultaneously impact the HIV and tuberculosis epidemics in South 
Africa [12].   
 While each modeling study has limitations and must be at least partially reliant on 
assumptions, these studies nevertheless add very meaningful analyses to debates about 
optimal strategies for combating HIV epidemics.  These models can be combined with 




1.4 Cost-effective analysis for HIV resource allocation 
 Cost-effectiveness analysis is a useful tool for helping healthcare decision makers 
determine how to best allocate resources across a defined number of competing needs to 
maximize health outcomes for a limited budget [13]. Many of the countries most severely 
affected by the epidemic, such as those in sub-Saharan Africa, are among the most 
resource-limited in the world.  Given the urgency of the situation, policy makers must 
often allocate resources with incomplete information, so predictive models that compare 
the costs and benefits of competing health interventions are important tools for guiding 
policy.  Where information is incomplete, sensitivity analyses can offer a range of 
possible outcomes based upon likely scenarios.   
 In earlier stages of the epidemic, cost-effectiveness analysis was used to inform 
debate among academics and policy makers about how to distribute investment between 
treatment and prevention programs for HIV in sub-Saharan Africa [14].  As prices for 
antiretroviral therapies have declined, global funding has increased, and model sites have 
demonstrated success in treating HIV in resource-poor settings, the debate has shifted 
from a focus on treatment or prevention to a broader question of how to best structure 
multifaceted HIV intervention programs. In this setting, cost-effectiveness analysis has 
been used to compare the health benefits and associated costs of different interventions 
and strategies.  For example, recent studies on HIV disease management have used cost-
effectiveness analysis to compare the use of different antiretroviral regimens[15], 
compare different methods of monitoring HIV[16], and evaluate when to best start 
HAART [17]. Cost-effectiveness analysis has also been used as a tool to measure the 
efficacy of different preventative interventions in sub-Saharan Africa, such as recent 
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research on male circumcision[18] and the widespread treatment of sexually transmitted 
infections, which is thought to reduce the likelihood of HIV transmission [19].    
 
1.4 Portfolio model of HIV interventions 
 While cost-effectiveness analysis has provided useful data to guide decision 
making on strategies to combat HIV/AIDS in resource-poor settings, a limitation of most 
studies is that they analyze a single intervention at a time, or directly compare two or 
more interventions.  In reality, strategies to combat HIV/AIDS will be multi-dimensional, 
with a number of interventions operating simultaneously.  Many of these interventions 
may have synergistic effects which are not captured in analyses that examine single 
interventions at a time.  For example, it is plausible that the presence of free antiretroviral 
medications will impact an individual’s willingness to obtain voluntary counseling and 
testing (VCT) services and that access to these services may influence an individual’s 
HIV risk behaviors [20].  Similarly, in some circumstances there are diminishing returns 
of multiple simultaneous interventions.  For example, one study may find that a certain 
preventive intervention may prevent one million HIV infections, and another study may 
find that a different intervention can prevent two million HIV infections.  However, this 
does not imply that the two interventions will prevent three million HIV infections 
because the target populations often overlap, and because infectious disease transmission 
occurs in a non-linear manner (i.e., the likelihood of contracting HIV depends on the 
fraction of individuals who are also infected).  Understanding how different interventions 
may affect the same population simultaneously is a limitation of existing HIV epidemic 
models. 
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 These examples highlight the need for models that can examine multiple 
interventions for HIV/AIDS simultaneously.  In her paper, Long describes a 
mathematical model that can be used to assess the effectiveness and the cost-
effectiveness of a portfolio of HIV interventions.  The model translates behavioral and 
biological factors influencing HIV transmission and disease progression into meaningful 
epidemic and economic outcome measures [21].  By altering the degree of each 
intervention, this model can estimate epidemiological and economic outcomes under 
different assumptions about clinical efficacy and individual behavioral responses to the 
interventions. 
 
1.5 Evaluation of HIV intervention portfolio in South Africa 
 We proposed to use Long’s intervention portfolio model to evaluate the 
heterosexual HIV epidemic in South Africa. By instantiating the model with 
epidemiologic data from South Africa, we evaluated how different portfolios of 
interventions impact the local epidemic. We chose to focus on three different 
interventions that have been shown to reduce new infections and improve the morbidity 
and mortality among infected individuals: male circumcision, voluntary counseling and 
testing (screening), and administration of highly active antiretroviral therapy.  While 
many other possible interventions exist, we chose to examine portfolios comprised of 
these three since they are applicable to a generalized heterosexual HIV epidemic. Recent 
papers have advocated for increased funding for each of these interventions as a possible 
means of making a major impact on the epidemic [9]. Also, papers have called for the 
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needs for more mathematical models of HIV epidemics to inform critical policy decisions 
[9]. 
 By using this model to examine how different portfolios of these interventions 
impact the epidemic in South Africa, we can then test the following hypothesis: the most 
effective and cost-effective strategy for improving the HIV heterosexual epidemic in 





We applied a dynamic compartmental epidemic model for HIV in South Africa 
which accounts for HIV transmission and disease progression for a generalized 
heterosexual HIV epidemic. Although the original model described in Long’s paper can 
account for transmission in certain high risk groups, for the purposes of this study, we 
focused only on heterosexual transmission and ignored transmission via injection drug 
use, homosexual contact, and from commercial sex workers (CSWs). We utilized the 
model to evaluate different portfolios of HIV interventions, each of which included a 
unique combination of three interventions: male circumcision, voluntary counseling and 
testing, and administration of highly active antiretroviral therapies (HAART). For each 
portfolio, we applied the model to estimate outcomes including HIV prevalence, new 
infections, costs, health benefits, and incremental cost-effectiveness ratios.  We evaluated 
the cost of each strategy on these epidemic and economic outcomes, to compare the cost-




Our model divides the adult South African population, aged 15 to 49, into 30 
compartments based on the following factors: gender, risk behavior, infection status 
(uninfected, asymptomatic HIV, symptomatic HIV, or AIDS) identification status 
(unidentified or identified), treatment status (receiving antiretroviral therapy or not), 
circumcision status (circumcised or not).  A schematic diagram of the compartmental 
model is shown in Figure 1. 
Individuals enter the model when they reach age 15 and exit the model at death or 
upon maturation beyond age 50.  The mortality rate for each compartment varies and is 
based upon previously published demographic data [22] . The movement of individuals 
between compartments is determined by transition probabilities based on the rates of 
disease transmission and disease progression.  
Disease-related mortality and disease progression rates for each compartment 
were based upon previously calculated data [23]. Quality of life factors for the different 
disease states were obtained from previously published sources [24] . These estimates 
allow the model to calculate the overall gain in health benefits as a result of reduced 
morbidity and mortality.   
2.3 Disease States 
  Each disease stage is defined according to CD4 T-cell count where asymptomatic 
HIV designates an individual who is HIV positive with a CD4 T-cell count >350 
cells/mm3, symptomatic HIV designates an individual who is HIV positive and has a 
 14
CD4 T-cell count between 200 and 350 cells/mm3, and AIDS designates an HIV positive 
individual with CD4 T- cell count below 200 cells/mm3. 
 
2.4 HIV Screening  
  Identification status denotes whether an individual is aware of his or her HIV 
status.  We assume that individuals learn of their HIV status through voluntary HIV 
counseling and testing services (VCT), and that individuals who participate in VCT 
reduce their annual number of sexual partners by 20%.  Individuals who receive VCT and 
test negatively for HIV remain identified as negative for two years before they transition 
back into a state where their HIV status is unknown. At this point these individuals are 
then eligible to be screened again. 
 
2.5 HIV Treatment  
The treatment for HIV is highly active antiretroviral therapy (HAART). We 
assume that in South Africa, only individuals with CD4 T-cell counts less than 200 
cells/mm3 are eligible to receive HAART, consistent with the World Health 
Organization’s guidelines for resource limited settings [25].  HAART has been 
demonstrated to reduce the HIV viral load in an individual and subsequently, to reduce 
the infectivity of an individual and the probability that the individual will transmit HIV to 
a sexual partner [26]. We assume that individuals receiving HAART experience a 
reduction in sexual infectivity of 90%, although we varied this value in sensitivity 
analysis. HAART also increases an individual’s life expectancy, and subsequently the 
length of time they can potentially infect their partners.  By using a dynamic model such 
 15
as the one we developed, we can evaluate how these opposing effects can influence 
epidemic outcomes. Financial costs and the quality of life benefits associated with using 
HAART are also taken into account for cost-effectiveness analysis. 
 
2.6 Male Circumcision 
Our model also assumes that currently 40% of South African adult men are 
circumcised, and that all adult men are capable of being circumcised.  We assume 
circumcision results in a 60% reduction in HIV acquisition for heterosexual males based 
on previously published data.[6-8] 
 
2.7 Disease transmission   
Data on sexual behaviors were obtained from a number of sources.  We used an 
average of 2.0 sexual partners per year for both males and females, from the South 
African Demographic and Health Survey[27].  We also assumed both males and females 
use latex condoms during 30% of episodes of sexual intercourse[4], and that condoms are 
90% effective in preventing transmission of HIV based upon previously published data 
[28]. 
Since our model is focused on the heterosexual HIV epidemic in South Africa, we 
only considered HIV transmission via heterosexual sexual contact and we ignored other 
modes of transmission including homosexual transmission, transmission via 
contaminated needles, and mother to child transmission. The annual probability of HIV 
transmission from male to female and from female to male is based upon previously 
published data. [10, 24]  These probabilities are then adjusted for the three HIV disease 
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states used in our model (asymptomatic HIV, symptomatic HIV, AIDS) and also for the 
presence of interventions (VCT, HAART, circumcision).   
Each of these stratifications allows for more precise modeling of an individual’s 
likelihood of acquiring or transmitting HIV and we adjust model parameters for each 
compartment accordingly.  
 
2.8 Model Implementation 
 The model is represented by a system of ordinary differential equations to track 
the number of people in each health state, or compartment, over time.  We instantiated 
the model based on population compartment sizes in 2007 and assumed a 20-year time 
horizon. 
 Parameters for the model were obtained from a combination of published primary 
and secondary data, calculations, and assumptions.  Table 1 shows all input parameters 
used in the model and their sources.  Our model assumed a South African adult 
population (defined as individuals aged 15-49) of 12,530,300 men and 13,464,600 
women based upon South African census data.  The HIV prevalence among these groups 
was 16.1% for men and 19.6% for women. Men and women were separated into 
compartments based on previously published sources, as shown in Table 1. Using the 
mathematical programming language Matlab, we numerically solved the system of 
equations for different HIV intervention portfolios in South Africa. 
 We began with a “base case” scenario that represented  the current use of the 
three interventions discussed, examined over a 20-year time horizon, and based on 
available 2007 data. In this base case, we assumed that 28% of all South African adults 
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with HIV and CD4 counts less than 200 cells/mm3 received antiretroviral treatment upon 
becoming eligible, and an additional 5% entered treatment programs annually.  We also 
assumed that 25% of all South African adults were tested for HIV and received the test 
results in the past two years. Finally, we estimated that 40% of adult males are 
circumcised and that this percentage will remain relatively constant. Under these base 
case assumptions, we then projected HIV prevalence, new HIV infections, and total costs 
and health benefits (measured in quality-adjusted life years or QALYs) incurred in the 
population, over the 20-year time horizon.  For each intervention portfolio, we then 
estimated the change in HIV prevalence, HIV infections prevented, incremental costs, 
incremental health benefits, and the incremental cost-effectiveness ratio (ICER) 
compared to the base case scenario. 
 
2.8.1 HAART focused portfolios 
 To create different scenarios to compare to the base case scenario, we altered the 
composition of the portfolio of interventions.  First, we examined hypothetical scenarios 
for changes in the percentage of HIV patients receiving HAART to explore how 
strategies that favor treatment scale up may affect the epidemic in South Africa. For these 
scenarios, the fraction of patients screened for HIV and the fraction of adult males 
circumcised remained constant with the base case. We created two separate “HAART-
focused” scenarios.  In the first scenario, we assumed that HAART access increases to  
50% of the eligible  HIV infected population (CD4 count <200 cells/mm3). We also 
created an “optimistic” scenario to examine HAART scale-up in South Africa.  In this 
case, we assumed that HAART access increases to  75% coverage. Again, we assumed 
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that the fraction of patients screened for HIV and the fraction of adult men circumcised 
remained constant. 
 
2.8.2 Screening Focused Scenarios 
 Next, we created scenarios that examined how intervention strategies that favored 
increased HIV screening impacted epidemic outcomes.  First, we created a “moderate” 
screening scenario, where we assumed that 50% of the adult South African population 
would be screened for HIV every two years.  For these screening focused scenarios, we 
held the percentage of South Africans receiving antiretroviral therapy, and the percentage 
of South African men circumcised constant from the base case.    We also created an 
additional “optimistic” screening focused scenario, where we assumed that 75% of the 
adult South African population is screened for HIV every two years, and otherwise 
followed the same assumptions as for the “optimistic” scenario.  
 
2.8.3 Circumcision Focused Scenarios 
 Next, we evaluated scenarios that favored widespread male circumcision.  In the 
base case scenario, we assumed that 40% of the adult South African male population is 
circumcised, and that this remains constant over the 20-year time horizon.  This means 
that each year as new fifteen year olds enter the adult population, we assume that 40% are 
circumcised. In the first circumcision focused portfolio, we assumed that every year 10% 
of the uncircumcised adult male population will become circumcised, in addition to the 
40% background circumcision rate.  In the second “optimistic” scenario, we increased the 
marginal circumcision rate to 20%.  For both of these scenarios we held constant the 
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percentage of HIV infected individuals receiving antiretrovirals, and the percentage of 
adults screened for HIV every two years. 
 
2.8.4 Combination Scenarios 
Finally, we evaluated different combinations of two or three interventions..  For 
each combination we considered a “moderate” and “optimistic” scenario.   
First, we evaluated portfolios that favored a combination of increased 
antiretroviral administration and increased screening. In these scenarios we assumed that 
the percentage of South African adult men who are circumcised stays constant at 40%.  In 
the moderate scenario, we assumed that 50% of eligible HIV infected individuals receive 
antiretroviral therapy, and 50% of South African adults undergo HIV screening every two 
years. In the optimistic scenario, we increased both interventions to 75% coverage. We 
then evaluated portfolios that favor a combination of increased antiretroviral 
administration and widespread circumcision, while maintaining only 25% HIV screening 
rates. In the moderate scenario, we increased antiretroviral therapy coverage to 50%, and 
increased the marginal circumcision rate to 10%. In the optimistic scenario, we increased 
the fraction of individuals receiving each intervention to 75% and 20%, respectively. The 
next combination of interventions favored increased screening for HIV and increased 
male circumcision.. In these two scenarios, the percentage of eligible individuals on 
HAART remained at 28%.  In the moderate scenario, we assumed that 50% of adults are 
screened for HIV every two years, and an additional 10% of uncircumcised men are 
circumcised.  In the optimistic scenario, these fractions increased to 75% and 20%, 
respectively.  
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Finally, we explored scenarios for portfolios which utilized all three interventions.  
In the moderate scenario, we assumed that 50% of eligible HIV infected South Africans  
receive HAART, 50% of adults are screened for HIV every two years, and 10% of 
uncircumcised men undergo circumcision each year.  In the optimistic scenario, the 
fraction of individuals receiving each intervention increases to 75% (HAART), 75% 
(screening), and 20% (male circumcision).   
 We used the Matlab software to solve for each of these 14 scenarios  to estimate 
how each portfolio affected the overall South African HIV epidemic, population-wide 
health benefits and costs, and incremental cost effectiveness, relative to the base case 
scenario. 
 
2.9  Student Contribution 
 Robert Stavert contributed by performing epidemiological research, conducting 
the literature review, gathering data on the South African HIV epidemic to be instantiated 
in the model, discussing relevant clinical assumptions, developing the scenarios evaluated 
by the model, and reviewing the results and conclusions.  All of this work was performed 




 In the base case scenario, we estimated that approximately 10.6 million people 
would become newly infected with HIV in South Africa over 20 years. At the end of the 
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20-year horizon, the HIV prevalence was 14.67% among men and 16.67% among women 
(Figure 2).   
 
3.1 HAART focused portfolios 
 The scenarios for HAART focused intervention portfolios resulted in the smallest 
number of infections prevented, compared to the base case scenario.  The moderate 
HAART focused scenario prevented 114,000 HIV infections (1.1% of projected new 
infections) compared to the base case, and the optimistic scenario prevented 242,000 
cases (2.3% of projected new infections) over twenty years (Figure 3). The moderate 
HAART focused strategy added 4.8 million QALYs, at a cost of $434 per QALY gained 
(Figure 4), and the optimistic scenario added 10.3 million QALYs at a similar cost per 
QALY gained (Figure 5). HIV prevalence among men declined modestly to 14.6% in the 
moderate scenario and 14.4% in the optimistic scenario (Figure 2).  Among women, these 
values were 16.5% and 16.4% respectively. HAART’s minimal reduction on HIV 
prevalence is in part due to infected individuals living longer as a result of treatment.  
Therefore, it is important to include in our analysis a universal metric, such as quality-
adjusted life years, to account for the effect of reduced mortality on health benefits.   
 
3.2 Screening focused portfolios 
The screening focused intervention portfolios prevented more infections than the 
HAART focused portfolios, but were more costly.  The moderate screening focused 
portfolio prevented 824,000 infections (7.8% of projected new infections) compared to 
the base case, and increased QALYs by 7.6 million at a cost of $433 per QALY gained 
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(Figures 3 and 4). In the moderate scenario the HIV prevalence in 20 years was 13.19% 
for men and 14.99% for women (Figure 2).  In the optimistic scenario, 1,387,000 
infections (13.1% of projected new infections) were prevented, adding 13 million 
QALYs at a cost of $499 per QALY gained (Figures 3 and 5). Screening-focused 
strategies offered a greater reduction in HIV prevalence than HAART-focused portfolios.  
After 20 years, HIV prevalence decreased to 13.19 % (moderate scenario) or 12.2% 
(optimistic scenario) among men and 15.0% (moderate scenario) or 13.9% (optimistic 
scenario) among women (Figure 2). 
   
3.3 Circumcision-focused portfolios 
 Among the portfolios focused upon a single intervention, the circumcision-
focused portfolios prevented the largest number of HIV infections.  The moderate 
scenario prevented 1,470,000 infections (13.8% of projected new infections), adding over 
13 million QALYs for only $55 per QALY gained (Figures 3 and 4). HIV prevalence fell 
to 11.1% in men and 14.1% in women at the end of the 20 years (Figure 2). Although 
circumcision primarily benefits men through reduced HIV acquisition, HIV prevalence 
notably decreases among women as well, due to reduced secondary transmission. 
Preventing one male HIV infection also prevents infection among future female partners, 
hence, HIV prevalence among women also decreased. The optimistic scenario was even 
more successful with 2,188,000 infections prevented over 20 years, with a net gain in 19 
million QALYs and a cost-effectiveness ratio of $62 per QALY gained (Figures 3 and 5). 
HIV prevalence substantially decreased to 9.7% and 12.8% for men and women 
respectively (Figure 2).  
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3.4 Combination Portfolios 
 We first considered intervention portfolios that include implementing two of the 
three interventions simultaneously.  In general, the number of infections prevented for a 
two-intervention strategy was less than the sum of implementing the interventions 
individually.  For example, under moderate assumptions, expanded screening prevented 
824,000 infections and expanded circumcision prevented 1,470,000 infections.  However, 
a portfolio that implemented these programs simultaneously prevented only 2,160,000 
infections (compared to 2,294,000 if implemented independently).  We find a similar 
result with QALYs gained: screening adds 7.6 million QALYs, circumcision adds 12.7 
million QALYs, and the combination strategy adds 19.3 million QALYs.  The benefits of 
implementing programs simultaneously are non-additive because the target populations 
for each intervention may overlap, and an infection cannot be prevented more than once.  
These results illustrate the need for using a dynamic epidemic model to appropriately 
evaluate the effects of multiple infectious disease interventions.   
Finally, we considered portfolios that scaled-up efforts of all three interventions.  
In the moderate scenario, this portfolio prevented 2,257,000 new HIV infections (21.2% 
of projected new infections) and increased QALYs by 23 million at a cost of $251 per 
QALY gained relative to the base case (and $484 relative to the circumcision-focused 
strategy) (Figures 3 and 4). HIV prevalence decreased to 9.9% among men and 12.6% 
among women (Figure 2).  Under optimistic assumptions, this portfolio averted 
3,414,000 HIV infections (32.1% of projected new infections), more than with any other 
strategy (Figure 3).  As expected, this strategy increased QALYs by the greatest amount 
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(38 million) at a cost of $305 per QALY gained relative to the base case (and $561 
relative to the circumcision-focused strategy) (Figure 5).  The favorable cost-
effectiveness ratios are largely driven by the relative inexpensiveness of male 
circumcision.  This strategy also offered the greatest reduction in HIV prevalence after 20 
years: 8.1% among men and 10.7% among women (Figure 2).  These were the lowest 
prevalence rates of all the scenarios examined. 
 
3.5 Sensitivity Analysis 
 We used sensitivity analyses to further evaluate areas of our model where there is 
a degree of uncertainty about the data or about future events.  One such area is the impact 
of VCT on behavioral risk reduction.  In the base-case of our model, we assume that 
individuals who undergo VCT reduce their number of sexual partners by 20%, as has 
been done in previously published studies [24].  In order to test the sensitivity of our 
findings to this assumption, we varied the risk reduction of individuals who undergo VCT 
from a minimum, where individuals do not change their risk behaviors at all after VCT, 
to a maximum where individuals reduce their sexual partners by 40% after VCT.  All 
intervention portfolios examined remain cost-effective, including the three-intervention 
combination portfolio, when there is no change in risk reduction after VCT.  Under these 
circumstances, the cost-effectiveness of the screening focused portfolios decreases as the 
ICER is $4,122, demonstrating the importance of the educational component of screening 
interventions. As the effectiveness of VCT in reducing risk behaviors rises, programs that 
use this intervention become relatively more cost-effective compared to the base case.  
When risk reduction is 10% the ICER of the moderate screening-focused portfolio is 
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$730, and when risk reduction is 40% the ICER of the moderate screening-focused 
portfolio is $278.  This finding again demonstrates the importance of adequately funding 
screening programs so that individuals who undergo VCT can receive helpful education 
about how to reduce the likelihood of acquiring HIV and transmitting it to a sexual 
partner.  
 Sensitivity analysis was also used to consider the effect of increased sexual 
activity among men who underwent circumcision.   Studies have reported increases in 
sexual risk taking behavior in populations where antiretroviral therapies become widely 
available [29].  There is concern that this trend may also apply to areas where male 
circumcision is applied as a preventive measure, although preliminary data indicates that 
this is not the case [30, 31].  We examined scenarios where male circumcision results in 
increased sexual activity from a range of 0% change in sexual activity to a 30% increase 
in sexual activity in individuals newly circumcised.  Our findings demonstrate that as 
sexual activity increases, overall costs increase, HIV prevalence increases, and the 
effectiveness of portfolios decrease.  However, even in the most pessimistic scenario 
where circumcision results in a 30% increase in sexual activity, the circumcision based 
portfolio still remains very cost-effective and has an ICER of $216, compared to an ICER 
of $55 when we assume 0% increase in sexual activity.  Similarly, the ICER of the 
moderate portfolio that combines all three interventions increases from to $251 from 
$422.  Thus, even in the event that circumcision leads to a substantial increase in sexual 
activity, portfolios with circumcision-based plans remain highly cost-effective. 
 In our initial scenarios, we assumed that HAART reduces the sexual infectivity of 
an individual by 90%. There is some uncertainty about the degree to which HAART 
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reduces infectivity, and there is also likely to be some variance from individual to 
individual depending on factors such as adherence, HIV genotype, and an individual’s 
genotype.  We varied the impact of HAART on infectivity from 90% in the base case to a 
minimum of 50% reduction in infectivity. This analysis results in fairly minimal changes 
in the overall costs and effectiveness of the portfolios studied.  The ICER of a HAART-
focused portfolio decreases from $552 to $434 as reduction in infectivity changes from 
50% to 90%.  Similarly, the ICER of the portfolio comprised of a combination of three 
intervention changes from $259 to $251.  Portfolios that include expanding access to 
HAART remain cost-effective even with only a 50% reduction in sexual infectivity 
because of the significant health benefits accruing among infected individuals receiving 
HAART. These findings demonstrate that the intervention portfolios are fairly robust to 
changes in the impact of HAART on infectivity.   
 
4. Discussion 
 In this study, we evaluated the costs, health benefits, and cost-effectiveness of 
expanded HIV screening, increased HIV treatment, and/or increased male circumcision 
using a dynamic HIV intervention portfolio model.  Our results highlight the significant 
opportunities that may exist to improve upon the current set of interventions aimed at 
controlling the generalized HIV epidemic in South Africa. The base case scenario 
projected that close to 11 million new HIV infections may occur in adults over a 20 year 
time horizon.  Our model can be applied to compare the relative costs and benefits of 
implementing various combinations of these three interventions, which may help policy 
makers allocate resources among competing interventions. Our results highlight the 
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urgency of increasing select HIV interventions, in order to most effectively mitigate the 
South African epidemic.   
 Of the portfolios that focused on a single type of intervention, the circumcision-
based portfolios were significantly more effective and less expensive than the portfolios 
which scaled up antiretroviral treatment and screening for HIV.  The cost of 
implementing circumcision programs is relatively low compared to other interventions, 
and circumcision is a single, safe event, if done in the appropriate healthcare setting, and 
an inexpensive mechanism for reducing HIV transmission. This finding is consistent with 
previous studies that have demonstrated that male circumcision is a highly cost-effective 
tool in South Africa.  One recent study found that “Male circumcision can lower health 
system costs. This finding is robust across a wide range of plausible parameter input 
values for South Africa, including lower effectiveness, higher costs, and lower HIV 
incidence.  This analysis also suggests that male circumcision is amongst the most 
economically efficient of HIV prevention strategies in sub-Saharan Africa.”[18] In our 
single intervention portfolios, the ICER of circumcision strategies was $55-$62, 
compared to $433-$499 for screening- and HAART-based strategies, further supporting 
the idea that widespread male circumcision should increasingly be considered as a 
strategy in South Africa.   
These findings also create opportunities for further research in this area.  
Epidemic modeling could be used to identify specific subpopulations to target for the 
most effective delivery of a circumcision campaign, for example men from particular age 
groups, men from particular locations in the country, or men with particular risk factors.  
The possibility of pursuing widespread circumcision as a prevention strategy also 
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demands that further research be undertaken to understand the personal and social 
meanings of this intervention in the variety of cultures and subcultures of South Africa.   
 Portfolios that used circumcision in combination with other interventions were 
more effective in preventing HIV infections than strategies that used individual 
interventions only, however they were also more costly.  The HAART and circumcision 
portfolios prevented 1.6 to 2.4 million HIV infections with an ICER of $151 to $177, 
while the screening and circumcision portfolios prevented 2.2 million to 3.2 million 
infections at an ICER of $209 to $262.  These findings demonstrate that while pursuing 
circumcision alone as a strategy may be effective, even further gains can be obtained by 
using circumcision in conjunction with other interventions.  However, as circumcision is 
used with other interventions the overall costs of programs escalate.   
 Additionally, when circumcision is added to existing portfolios of interventions, 
the portfolios become more effective and more cost effective.  When the circumcision 
intervention is added to the HAART portfolio, the number of infections prevented 
increases substantially from 114,000-242,000 to 1.6-2.4 million, and the ICER decreases 
from $434-$433 to $151-$177.  A similar effect is noted when a circumcision 
intervention is added to the screening portfolio.  In that case, the number of new 
infections prevented increases from approximately 824,000-1.4 million to 2.2 million-3.2 
million.  The ICER falls from $433-$499 to $209-$262. This finding suggests that adding 
a widespread circumcision intervention to the treatment and screening interventions 
currently in place may offer significant benefits. 
 In the final scenario created, we examined a strategy that used a combination of 
all three interventions.  This strategy was the most effective overall in averting HIV 
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infections but with a slightly higher incremental cost-effectiveness ratio: $251-$305 
relative to the base case (or $484-$561 relative to circumcision-focused strategies).  The 
World Health Organization suggests that health interventions are “very cost-effective” if 
they cost less than gross domestic product (GDP) per capita, and “cost-effective” if they 
cost less than three times GDP per capita [32].   Based on these guidelines, this particular 
HIV intervention portfolio falls significantly below the WHO’s threshold.    These 
findings again suggest that the largest number of infections is prevented with portfolios 
that are multifaceted and that it is possible to avert large numbers of infections with 
moderate increases in overall program cost. 
 Our study model and findings are limited by a number of factors.  Because of 
limited data, we did not stratify certain populations who may have a higher risk of 
acquiring or transmitting the HIV virus than the general population.  In particular, we do 
not have separate compartments for commercial sex workers, intravenous drug users, or 
men who have sex with men.  Individuals in each of these groups may influence the 
shape of the HIV epidemic in South Africa in ways that are unaccounted for in our 
model.   
 A few studies have recently attempted to learn more about the HIV epidemic 
among men who have sex with men in sub-Saharan Africa and found that as in other 
regions of the world, African men who have sex with men also have sex with women 
[33]. This means that men who have sex with men are likely to shape the heterosexual 
HIV epidemic in South Africa.  However, the extent of this influence is not clear. 
 Similarly, data on injection drug use behavior in South Africa are very limited, 
but some information is beginning to emerge.  According to a UNAIDS review, injection 
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drug use is an increasingly important factor in HIV epidemics in the region, and one 
study found 28% of drug users tested in South Africa to be HIV positive [34].  In 
addition, in other areas of sub-Saharan Africa a majority of drug users interviewed were 
found to share needles with other drug users, and were also found to be sexually active 
[34]. As more data on these high risk groups become available, incorporation of this data 
into our epidemic model will allow for more precise estimates of how these groups 
influence the HIV epidemic in South Africa and the success and costs of different 
interventions.  
Our model is also limited by the ability of the model to predict future events. One 
such area is projection of the use and costs of second line antiretroviral therapies. 
Currently, the cost of second line therapies for HIV far exceeds cost for first line 
therapies in South Africa. A recent WHO report found that the current prices for the most 
common first line antiretroviral regimens in lower middle income countries fell in a range 
from about $140 per patient per year to $380 per patient per year [35]. However, prices 
for the most common second line antiretroviral therapies were in the range of about 
$1300 to $2700 per patient per year [35]. Currently, South Africans on second line 
antiretrovirals make up a small minority of South African patients on HAART. However, 
as treatment plans are scaled up and more patients with HIV are treated with HAART, for 
longer periods of time, the number of patients who must be treated with second line 
HAART increases rapidly.  Another WHO  report estimates that approximately 3% of 
patients receiving HAART, per year, must switch from first line to second line therapies, 
as patients develop strains of HIV that are resistant to first line therapies, or because they 
are unable to tolerate the toxicities of particular medications [36].     
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Depending on how this is projected over time, the cost of second line therapies 
has a major impact on the overall cost of scaling up treatment. One report estimates that 
by the year 2010, second line antiretrovirals will make up 90% of the cost of providing 
antiretroviral therapies to low and middle income countries [37].    Projecting the use and 
costs of second line antiretrovirals in South Africa twenty years into the future is very 
challenging, as the prices of second line antiretrovirals are a subject of debate and 
negotiation between drug manufacturers, governments, and non-governmental 
organizations.  Although it is reasonable to predict that prices for second line 
antiretrovirals in South Africa are likely to decline during the twenty year time horizon of 
our model, the extent and timing of this decline is difficult to predict and significantly 
impacts the cost of scaling up treatment. In the future, the model can be used to 
demonstrate the effect of second line antiretrovirals on the overall cost of scaling up 
antiretroviral therapy as prices for these therapies change and more data emerges about 
antiretroviral switch rates.  
Another opportunity to expand the data provided by our model would be to create 
different scenarios depending on when HAART is initiated.  In our model, HAART is 
initiated only in for a percentage of patients whose CD4 T-cell count is below 200 cells/ 
mm3; patients with CD4 counts above 200 cells/mm3 are not candidates for HAART even 
if they otherwise meet WHO recommendations for HAART initiation. Initiating HAART 
earlier in the course of an individual’s HIV disease provides a greater opportunity to 
reduce HIV-related morbidity and the likelihood of transmitting the virus to partners.  
Future studies could examine how varying the criteria for HAART initiation impacts the 
effectiveness and cost of the portfolios of interventions described in this study. 
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5. Conclusions 
 In this paper we describe the results of a study that uses a deterministic computer 
model to explore the impact of different portfolios of interventions on the adult 
heterosexual HIV epidemic of South Africa.  Our study finds that portfolios which 
incorporate widespread circumcision as a preventive intervention are generally more 
effective and cost-effective than other portfolios  that exclusively focus on expanded HIV 
screening and/or treatment with HAART.  Portfolios that combine a scale up of voluntary 
counseling and testing resources, scale of up antiretroviral administration, and 
widespread circumcision campaigns were the most successful overall in reducing new 
infections and adding QALYs over the 20-year time horizon explored.  We also find that 
the costs and benefits of implementing multiple HIV interventions simultaneously are 
non-additive, and a dynamic epidemic model such as the one we have implemented is 
necessary in order to accurately estimate the effect of compound interventions on 
epidemic and economic outcomes.  In the absence of a clinical trial offering a similar 
amalgamation of interventions, a mathematical model is the best tool for estimating the 
costs and benefits of a portfolio of HIV interventions.  In this study, we included only 
three interventions; however, our modeling framework could be extended to include 
additional interventions (e.g., a preventative vaccine, microbicide, genetic therapy) 
should they become available in the future. 
 While the findings of this paper are intended to inform debates and discussions 
about the optimal use of limited resources to combat the HIV epidemic in South Africa, 
there are multiple limitations inherent in a mathematical model. Mathematical models are 
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limited by the quality of the data used to generate estimates, and are based upon events 
which have happened in the past and may not be necessarily predictive of the future.   
Mathematical models may also not sufficiently account for costs and benefits that 
are difficult to quantify.  For example, increasing the availability of HAART in South 
Africa is likely to have significant societal benefits not accounted for in the metrics of our 
model, such as an increased life expectancy for parents, greater social stability, and 
greater productivity leading to economic gains.  Despite these shortcomings, the findings 
of this study can be helpful as policy makers face difficult choices in allocating resources 
to combat the HIV epidemic in South Africa.  We hope that in the future we can apply 
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Table 1:  Model Input Parameters, Values, Source 
 
Parameter Value Source 
Demographic Parameters   
Total population (15-49 year olds)   
     Males 12,530,300 [38] 
     Females 13,464,600 [38] 
HIV prevalence   
     Males 16.1% [38] 
     Females 19.6% [38] 
Fraction of HIV-infected individuals   
     Asymptomatic HIV (CD4 >350) 50% [39] 
     Symptomatic HIV  (CD4 200-350) 30% [39] 
     AIDS (CD4 <200) 20% [39] 
Mortality rate (non-HIV-related)   
     Male 0.028 [10] 
     Female 0.028 [10] 
Maturation rate   
     Male 0.0162 [38] 
     Female 0.0185 [38] 
Entry rate (includes growth rate)   
     Male 0.0623 [38], [34] 
     Female 0.0587 [38], [34] 
   
   
Disease Parameters   
Disease mortality rate   
     Asymptomatic HIV (CD4 >350) 0.01 [22] 
     Symptomatic HIV  (CD4 200-350) 0.02 [22] 
     AIDS (CD4 <200) 0.45 [22],[40] 
     AIDS (CD4 <200) on HAART 0.11 [22], [39] 
Disease progression rate   
     Asymptomatic HIV (CD4 >350) 0.1745 [22] 
     Symptomatic HIV  (CD4 200-350) 0.2755 [22] 
     AIDS (CD4 <200) --  
     AIDS (CD4 <200) on HAART --  
Quality-of-life factor   
Uninfected 1.0 [41] 
Asymptomatic HIV (CD4 >350)   
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Parameter Value Source 
     Unidentified 0.91 [42], [24] 
     Identified – First Year 0.84 [24], [43] 
     Identified – Subsequent Years 0.89 [24] 
Symptomatic HIV  (CD4 200-350)   
     Unidentified 0.79 [24], [43], [44], [45] 
     Identified 0.72 [42] 
AIDS (CD4 <200)   
     Unidentified 0.72 [24] 
     Identified 0.72 [44], [45], [43] 
     Identified and on HAART 0.82 [45] 
   
   
Sexual Behavior Parameters   
Annual probability of HIV transmission per 
sexual partnership (FHIV+ MHIV-) 
  
     Asymptomatic HIV (CD4 >350) 0.05 [24], [10], [46] 
     Symptomatic HIV  (CD4 200-350) 0.08 [24],  [10], [46] 
     AIDS (CD4 <200) 0.10 [24],  [10],  [46] 
Annual probability of HIV transmission per 
sexual partnership (MHIV+ FHIV-) 
  
     Asymptomatic HIV (CD4 >350) 0.10 [24], [10],[46] 
     Symptomatic HIV  (CD4 200-350) 0.15 [24], [10],[46] 
     AIDS (CD4 <200) 0.20 [24],[10],[46] 
Average number of sexual partners per year   
     Males 2.0 [27] 
     Females 2.0 [27] 
Condom usage    
     Males 30% [47]  
     Females 30% [47] 
Condom effectiveness 90% [10] 
   
   
Screening & Identification Parameters   
Fraction of uninfected population identified 
(HIV-tested in past 2 years) 
25% [48] 
Identification duration if uninfected (years) 2 [27] 
Fraction of infected population identified 35% [48] 
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Parameter Value Source 
Annual probability of symptom-based case 
finding if infected 
  
     Symptomatic HIV (CD4  200-350) 0.1 [24] 
     AIDS (CD4 <200) 0.2 [24] 
Reduction in sexual behavior due to 
screening 
  
     Uninfected 20% [24] 
     HIV-Infected 20% [24] 
Treatment Parameters   
Fraction of eligible individuals receiving 
HAART at CD4 <200 
28% [34] 
Reduction in sexual infectivity due to 
HAART 
90% [24], [9], [49] 
   
   
Circumcision Parameters   
Fraction of males circumcised 40% [34], [48], [27] 
Reduction in HIV acquisition due to 
circumcision (heterosexual males) 
50% 
 
[7], [6], [8] 
 
   
   
Cost Parameters (2008 USD)   
Annual HIV-related healthcare costs   
     Asymptomatic HIV  (CD4 200-350) $574 [22] 
     Symptomatic HIV (CD4 >350) $852 [22] 
     AIDS (CD4 <200) $4,257 [22] 
     AIDS (CD4 <200) on HAART $736 [22] 
Annual non-HIV-related healthcare costs $856 [1] 
Annual cost of HAART $142 [35] 
Cost of testing and counseling $74 [50] 
Cost of circumcision $64 [18] 
Annual discount rate 3% [51] 
   























ICER relative to 
Base Case Next Best
      
HAART-focused      
     Moderate 113,656 $2.10 4.85 $434 Dominated
     Optimistic 242,075 $4.45 10.28 $433 Dominated
      
Screening-focused      
     Moderate 824,040 $3.30 7.62 $433 Dominated
     Optimistic 1,387,800 $6.48 12.97 $499 Dominated
      
Circumcision-focused      
     Moderate 1,470,789 $0.70 12.73 $55 $55 
     Optimistic 2,187,508 $1.20 19.31 $62 $62 
      
Combination       
     Moderate 2,256,555 $5.89 23.45 $251 $484 
     Optimistic 3,413,878 $11.50 37.64 $305 $561 
      
 
Under the base case, approximately 10.8 million HIV infections occur over 20 years. 
Incremental costs and quality-adjusted life years (QALYs) are relative to the base case. 
Incremental cost-effectiveness ratio (ICER) is relative to the base case or the next-best 
alternative, assuming all strategies are either moderate or optimistic. 




































































































Symptomatic HIV AIDS 
UnID = Unidentified 
ID = Identified 
Circ = Circumcised 
ART = Antiretroviral Therapy 
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Figure 2: HIV Prevalence in Men and Women by Intervention Portfolio 
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